Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Boston Scientific (BSX) is 6/10.
Boston Scientific's Q1 FY2026 saw full-year guidance lowered on three business headwinds: WATCHMAN growth decelerating from practice pattern shifts, EP competitive pressure from three large PFA entrants, and urology commercial disruption. Revenue grew 11.6% with 9.4% organic, but organic growth guidance was cut to 6.5-8% and EPS to $3.34-$3.41. The CHAMPION trial validated WATCHMAN clinical evidence, and a robust 2027 pipeline featured three major PFA launches.
Scored from Boston Scientific’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
On August 25, 2026, Boston Scientific identified a cybersecurity incident affecting certain IT systems that resulted in a global disruption to operations. The Company activated incident response protocols and engaged third-party experts to contain and investigate the threat. The incident has caused, and is expected to continue causing, disruptions and limited access to systems and applications supporting operations, including the ability to process and ship customer orders.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $4.56B | +22.4% | $0.38 | +11.3% | 58.6% | 12.9% | 12.4% | $1.16B |
| FY2025 Q1 | $4.66B | +20.9% | $0.45 | +35.1% | 63.3% | 19.2% | 14.5% | $354M |
| FY2025 Q2 | $5.06B | +22.8% | $0.53 |
| +142.8% |
| 67.7% |
| 16.2% |
| 15.7% |
| $1.10B |
| FY2025 Q3 | $5.07B | +20.3% | $0.50 | +58.6% | 69.9% | 20.7% | 14.9% | $1.16B |
| FY2025 Q4 | $5.29B | +15.9% | $0.45 | +18.5% | 74.5% | 22.8% | 12.6% | $1.01B |
| FY2026 Q1 | $5.20B | +11.6% | $0.90 | +99.4% | 69.4% | 20.6% | 25.7% | $171M |
| FY2026 Q2 | $5.44B | +7.5% | $0.61 | +15.1% | 70.7% | 21.6% | 16.7% | — |